GeneMedi's Tumor-associated antigen (TAA) portfolio for anti-cancer drug discovery and mechanism of action (MOA) research.

GeneMedi's Tumor-associated Antigen (TAA) portfolio boasts a suite of research products that include recombinant proteins, antibodies, and genes that are overexpressed in tumor cells. These products serve as valuable tools for identifying and characterizing potential diagnostic markers and therapeutic targets for cancer treatment.

Tumor-associated antigens are proteins expressed by cancer cells that are recognized by the immune system as foreign. They play a crucial role in identifying and eliminating cancer cells from the body. Tumor-associated antigens are classified based on their structural and functional properties. One widely used classification divides TAAs into two primary categories: shared antigens and unique antigens. Shared antigens, such as carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and human epidermal growth factor receptor 2 (HER2/neu), are commonly expressed in various cancer types. Unique antigens, such as melanoma-associated antigen (MAGE), cancer-testis antigen (CTA), and NY-ESO-1, are expressed only in specific cancer types. The identification and targeting of tumor-associated antigens and associated signaling pathways have led to the development of several diagnostic and therapeutic applications. TAAs are promising targets for drug development, with monoclonal antibodies and cancer vaccines already being used to treat various cancers. Additionally, TAAs can also be used as diagnostic markers for certain cancers, such as CEA or PSA for colorectal or prostate cancer, respectively.

Overall, TAAs represent an important therapeutic target for precision medicine and personalized therapies, with significant potential for drug discovery and development. GeneMedi provides benchmark antibodies for various research applications of TAAs, including ELISA, affinity binding assays, drug discovery, and mechanism of action research. Our pre-made monoclonal antibodies are expressed using mammalian cell lines to ensure high quality and reproducibility, and they are useful as reference therapeutic antibodies for various research applications, including cell culture, assay development, animal model development, PK/PD model development, and MOA research in biological drug discovery.

Q&A

Q1. What are tumor-associated antigens?
A1: Tumor-associated antigens (TAAs) are proteins expressed by cancer cells that are recognized by the immune system as foreign.

Q2. How are TAAs classified?
A2: TAAs can be classified based on their structural and functional properties into shared antigens and unique antigens.

Q3. What is the significance of identifying TAAs?
A3: The identification and targeting of TAAs and associated signaling pathways have led to the development of several diagnostic and therapeutic applications for cancer treatment.

Q4. What research products does GeneMedi offer for TAAs?
A4: GeneMedi offers a variety of research products, such as recombinant proteins, antibodies, and genes that are overexpressed in tumor cells.

Q5. What are the potential applications of TAAs?
A5: TAAs represent a promising target for personalized therapies and precision medicine, with significant potential for drug discovery and development. They also serve as diagnostic markers for certain cancers, such as CEA and PSA for colorectal and prostate cancer, respectively.